JMAR Technologies Files Form 10-K

SAN DIEGO--(BUSINESS WIRE)--April 11, 2006--JMAR Technologies, Inc. (NASDAQ: JMAR), a leading developer of advanced laser technology, today filed its Form 10-K for the year ending December 31, 2005. In a press release dated March 30, 2006 and in the Company's conference call on that same day, JMAR announced that its audit was not completed and it would not be able to timely file its 2005 Form 10-K by the March 31, 2006 deadline. On April 3, 2006, the Company filed a Form 12b-25 which provided for an extension until April 17, 2006 to file its Form 10-K.

Consistent with prior audit opinions received by the Company, the audit opinion included in the Form 10K filed today does not include a going concern modification. This clean opinion is supported by management's assertion in the Form 10-K that the Company's recent financings provide adequate financial resources through December 31, 2006 to conduct the Company's business. In addition, there were no changes to the previously reported amounts for the quarter and year ended December 31, 2005.

About JMAR

JMAR Technologies, Inc. is a leading innovator in the development of laser-based equipment for imaging, analysis and fabrication at the nano-scale. The Company is leveraging more than a decade of laser and photonics research to develop a diverse portfolio of products with commercial applications in rapidly growing industries while continuing to carry out work for the U.S. Government. JMAR is targeting the nanotechnology, bioscience and semiconductor industries with its BriteLight(TM) Laser; X-ray Light Source; Compact X-ray Microscope - for 3D visualization of single cells and polymers; and X-ray Nano Probe - enabling interaction, analysis and materials modification at the nano-scale. JMAR also develops, manufactures, and markets its BioSentry(TM) microorganism early-warning system and maintains a strategic alliance for the production of the READ chemical sensor for the homeland security, environmental and utility infrastructure industries.

This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. Actual results could differ materially from these forward-looking statements as a result of a number of factors, including the risk that the performance validation tests of the BioSentry Beta units are not successfully completed due to unforeseen issues with the installation and operation of the units outside of the controlled environment of JMAR's facility, delays in completion of the X-ray Microscope and X-ray Nano Probe prototypes and transition to production units, the failure of the technology to perform as predicted, competition from alternative technologies, uncertainties as to the size of the markets , cost and margins for JMAR's products, failure to obtain market acceptance, current or future government regulations affecting the use of JMAR's products, the lack of availability of critical components, the degree of protection from future patents, other risks associated with the development or acquisition of new products or technologies and those risks detailed in the Company's Form 10-K for the year ended December 31, 2005 filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. JMAR Technologies, Inc. does not assume any duty to publicly update or revise the material contained herein.


JMAR Technologies, Inc.
Dennis E. Valentine
Chief Financial Officer
The Investor Relations Group
Katrine Winther-Olesen/Tom Caden
IR/Media Relations

Better Be Business Wired.

Business Wire is the leading source for press releases, photos, multimedia and regulatory filings from companies and groups throughout the world.